Literature DB >> 26390247

Community-based provision of family planning in the developing world: recent developments.

Morrisa A Malkin1, John Stanback.   

Abstract

PURPOSE OF REVIEW: The study reviews important contributions to the peer-reviewed literature on the community-based provision of family planning in developing countries, from 2012 to the present. RECENT
FINDINGS: The major areas on which recent reports have focused include pilot studies, drug shops, and new contraceptive technology. The key studies focus largely on the provision of injectable contraception at the community level.
SUMMARY: Decades of previous research on community-based family planning has focused on the traditional community health worker. Yet, recent developments in this field have expanded many areas that have been studied previously. A major emphasis of recent research has dealt with broadening the community-based locations from which clients can obtain injectable contraception. Drug shops in developing countries are promising locations for family planning services. They are ubiquitous, frequently accessed, and generally sustainable businesses. Also, a new formulation of injectable contraception in an easy-to-use delivery device is garnering global attention for its potential benefits in community-level use. Additional research and programmatic interventions are needed to better understand the training, policy, regulatory, and logistical needs to ensure quality service delivery.

Mesh:

Substances:

Year:  2015        PMID: 26390247     DOI: 10.1097/GCO.0000000000000214

Source DB:  PubMed          Journal:  Curr Opin Obstet Gynecol        ISSN: 1040-872X            Impact factor:   1.927


  1 in total

1.  Integrating preexposure prophylaxis delivery in routine family planning clinics: A feasibility programmatic evaluation in Kenya.

Authors:  Kenneth K Mugwanya; Jillian Pintye; John Kinuthia; Felix Abuna; Harrison Lagat; Emily R Begnel; Julia C Dettinger; Grace John-Stewart; Jared M Baeten
Journal:  PLoS Med       Date:  2019-09-03       Impact factor: 11.069

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.